Request Demo

Last update 08 May 2025

TEDA International Cardiovascular Hospital

Hospital|Tianjin Shi, China

Last update 08 May 2025

Overview

Pipeline

Deal

Translational Medicine

Overview

Basic Info

Introduction

TEDA International Cardiovascular Hospital is a medical facility that focuses on treating cardiovascular diseases. Located in the Binhai New Area of Tianjin, China, this hospital is dedicated to providing specialized care for patients with heart and vascular conditions.

Drugs associated with TEDA International Cardiovascular Hospital

Mesenchymal Stem Cells( Beijing Yuanhefa Biotechnology)

Target-

Mechanism-

Active Org.-

Originator Org.

Beijing Yuanhefa Biotechnology Co., Ltd.

Active Indication-

Inactive Indication

Acute myocardial infarction [+1]

Drug Highest PhasePending

First Approval Ctry. / Loc.-

First Approval Date-

Clinical Trials associated with TEDA International Cardiovascular Hospital

ChiCTR2300075991

/ SuspendedPhase 4IIT

Efficacy of tirofiban for acute cerebral infarction presenting beyond the time window for intravenous thrombolytic therapy

Start Date30 Sep 2023

Sponsor / Collaborator

TEDA International Cardiovascular Hospital

NCT06340048

/ RecruitingPhase 1/2

Epicardial Injection of Allogeneic Human Pluripotent Stem Cell-derived Cardiomyocytes to Treat Severe Chronic Ischemic Heart Failure

The purpose of this clinical study is to evaluate the feasibility, safety and efficacy of intramyocardial injection of human induce pluripotent stem cell-derived cardiomyocytes (HiCM-188) during coronary artery bypass grafting (CABG) surgery in patients with severe chronic ischemic heart failure.

Start Date05 Sep 2023

Sponsor / Collaborator

Help Therapeutics Ltd.

[+1]

NCT05824923

/ RecruitingPhase 3

A Prospective, Multicenter, Randomized Controlled Trial to Evaluate the Safety and Efficacy of Single-use Ring-shaped Pulmonary Artery Radiofrequency (RF) Ablation Catheter and Pulmonary Artery RF Ablation Generator for the Treatment of Pulmonary Hypertension Associated With Left Heart Failure

It's a phase III, prospective, multicenter, randomized controlled trial to evaluate the safety and efficacy of the pulmonary artery denervation (PADN) for heart failure (HF) patients diagnosed with pulmonary hypertension associate with left heart disease (PH-LHD) by right heart catheterization.

Start Date14 Aug 2023

Sponsor / Collaborator

Pulnovo Medical (Wuxi) Co., Ltd.

[+32]

100 Clinical Results associated with TEDA International Cardiovascular Hospital

0 Patents (Medical) associated with TEDA International Cardiovascular Hospital

545

Literatures (Medical) associated with TEDA International Cardiovascular Hospital

01 May 2025·Redox Biology

Protein post-translational modification crotonylation of TXN and GLO1 in artery and vein grafts for coronary artery surgery

Article

Author: Hou, Hai-Tao ; Xue, Hong-Mei ; Sun, Wen-Tao ; He, Guo-Wei ; Yang, Qin ; Chen, Huan-Xin

A key problem in coronary artery bypass grafting (CABG) is the lower long-term patency of the saphenous vein (SV) compared to internal thoracic artery (ITA). The potential strategies to improve the long-term patency of the vein graft include developing drugs to block unfavorable pathways in the vein and even to change the protein structure of the vein towards arterial structure. It is therefore important to understand the differences of the protein structure between arterial and venous grafts. Using post-translational modification (PTM) proteomics, we systematically investigated differences between ITA and SV with regard to a vascular stenosis-related PTM crotonylation. Crotonylome and PTM crotonylation in paired ITA and SV segments (n = 150) from patients undergoing CABG surgery were performed by proteomics analysis with further validation. To elucidate the underlying mechanisms, we focused on three crotonylated enzymatic proteins with anti-oxidative effects-thioredoxin (TXN), glyoxalase 1 (GLO1), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) - whose crotonylation patterns were systematically investigated. The functional validation was performed using both site-mutation experiments in HEK293 cells and pharmacological inhibitors in ex vivo cultured ITA/SV tissue specimens. Comprehensive crotonyl-proteomics demonstrated 3652 proteins are differentially-expressed and 411 proteins are differentially-crotonylated in ITA/SV segments. In the identified crotonylated proteins, SV demonstrated significantly higher levels compared to ITA. Notably, SV showed higher crotonylation levels on TXN-K3, GLO1-K157, and GAPDH-K61, which were associated with decreased enzymatic activity, elevated methylglyoxal (MGO) accumulation, and increased oxidative stress. Inhibition of CREB-binding protein (CBP) reversed oxidative stress in SV by suppressing crotonylation of the three enzymes. In Hek293 cells, both site-specific and comprehensive crotonylation decreased the activities of TXN/GLO1/GAPDH, which in turn triggered the accumulation of MGO. Overexpression of histone deacetylases HDAC1 and HDAC3 showed the opposite effect, restoring enzyme function. This study is the first to reveal significant differences in PTM crotonylation between human ITA and SV, shedding light on the biological mechanisms underlying the functional disparities between these grafts. These differences impact the enzymatic activity of key proteins involved in oxidative stress, providing insights into the molecular basis of graft performance. Importantly, these findings form a scientific basis for developing specific methods including new anti-oxidative drugs and gene therapy to target on crotonylation in the vein graft in order to improve the long-term graft patency.

01 Apr 2025·Herz

Acute atrial infarction: a relatively neglected and under-recognized entity in clinical practice

Article

Author: Zhang, Yan ; Li, Longyu ; Wang, Haijiang ; Lin, Wenhua ; Wang, Mingming ; Wu, Yanxi ; Di, Chengye ; Wang, Qun

BACKGROUNDElectrocardiograms (ECGs) and angiographic features indicative of acute atrial infarction (AAI) often go unnoticed and are under-recognized in clinical practice.METHODSIn this retrospective observational study, we analyzed the data of 3981 out of 9803 patients (40.61%) who were referred to our hospital for angiography and/or percutaneous coronary intervention due to acute coronary syndrome (ACS). These patients were diagnosed with acute ST segment elevation myocardial infarction (AMI) affecting the inferior, posterior, and/or right ventricular regions.RESULTSOf the 3981 patients, 270 (6.78%) had involvement of the main coronary atrial branch meeting the angiographic criteria for AAI. Among the 270 patients identified, the right coronary artery was diagnosed as the infarct-related artery (IRA) in 187 patients (group R), while the left circumflex artery was the IRA in 83 patients (group L). The incidence of PR-segment deviation was similar between the two groups (65.2% in group R vs. 66.3% in group L, p = 0.870), as was occurrence of atrial tachyarrhythmia (67.4% vs. 55.4%, p = 0.059). The prevalence of P wave morphology abnormalities (29.9% vs. 49.4%, p = 0.005) and sinus bradycardia or arrest (25.1% vs. 66.3%, p < 0.001) was significantly lower in Group R than in Group L.CONCLUSIONAcute atrial infarction represents a distinct yet frequently overlooked clinical entity. Clinicians should consider the potential for atrial arrhythmias, thromboembolism, hemodynamic instability, and atrial rupture when diagnosing AAI.

01 Apr 2025·Biochemical Pharmacology

Contributing role and molecular basis of Vitamin D/Vitamin D receptor deficiency in hyperhomocysteinemia-induced cardiac hypertrophy

Article

Author: Qi, Hang ; Yang, Qin ; He, Guo-Wei ; Hou, Hai-Tao ; Wei, Jia-Hui ; Zhou, Yang

Hyperhomocysteinemia and vitamin D deficiency are known to promote cardiac hypertrophy, however, whether vitamin D signaling is involved in hyperhomocysteinemia-induced cardiac hypertrophy remains unexplored. This study aimed to address this question by clarifying the effect of homocysteine on vitamin D and vitamin D receptor (VDR), with further elucidation of the regulatory mechanisms. Methionine diet-induced hyperhomocysteinemic (HHcy) rats and homocysteine-incubated cardiomyocytes were used as in vivo and in vitro models of cardiac hypertrophy. Gain-and-loss-of function of VDR and miR-125b-5p were achieved by plasmid transfection and AAV9-mediated delivery. HHcy rats showed lowered serum and cardiac 1,25(OH)₂D₃ levels and increased 24-hydroxylase (CYP24A1) expression in kidney and myocardium. VDR expression was downregulated and miR-125b-5p was upregulated in the myocardium of HHcy rats and in homocysteine-incubated cardiomyocytes as well. Knockdown of VDR facilitated while overexpression mitigated homocysteine-induced cardiomyocyte hypertrophy, accompanied by activation and inhibition of calcineurin/nuclear factor of activated T cells 4 (NFATc4) respectively. Dual-luciferase reporter gene assay and gain-and-loss-of function of miR-125b-5p in cardiomyocytes indicated the targeting and repressing of VDR by miR-125b-5p and its pro-hypertrophic effect. The role of miR-125b-5p-mediated VDR downregulation in homocysteine-induced cardiac hypertrophy was further demonstrated in vivo. Treatment with VDR agonist inhibited hypertrophic growth both in vivo and in vitro, resulting from VDR upregulation and consequent calcineurin/NFATc4 inhibition. These findings demonstrated that homocysteine reduces 1,25(OH)₂D₃ level in both plasma and myocardium via upregulating CYP24A1 and represses myocardial VDR expression via the mediation of miR-125b-5p. Vitamin D/VDR deficiency contributes to hyperhomocysteinemia-induced cardiac hypertrophy via activating calcineurin/NFATc4 pathway.

News (Medical) associated with TEDA International Cardiovascular Hospital

26 Sep 2023

·www.prnewswire.com

Teda International Cardiovascular Hospital helps children with congenital heart disease

BEIJING, Sept. 26, 2023 /PRNewswire/ -- A report from China Daily: On Sept 22, 27 children with congenital heart disease from Yushu Tibetan autonomous prefecture in Qinghai province arrived at Teda International Cardiovascular Hospital in Tianjin's Binhai New Area for free treatment. Continue Reading Teda International Cardiovascular Hospital With ages ranging from 6 months to 16 years, they had been diagnosed with various types of congenital heart diseases when the hospital's staff conducted free congenital heart disease screening on 400 children in Qinghai's remote counties from Sept 11 to 20. These children were given the opportunity to receive free surgery at Teda International Cardiovascular Hospital. Since its establishment, Teda International Cardiovascular Hospital has collaborated with the Ministry of Civil Affairs and various social charity organizations to carry out a series of charitable projects aimed at support underprivileged children with congenital heart disease. To date, they have provided treatment to over 16,000 affected children, covering 28 provinces and 33 ethnic groups. Congenital heart disease is a congenital anomaly resulting from the abnormal development of the heart and blood vessels during fetal development. It ranks as the leading cause of death among newborns and is one of the primary causes of death in children under the age of five. Early detection and treatment are crucial in helping children with congenital heart disease regain their health. Guo Zhonghong, one of the first children to receive treatment, successfully underwent surgery, excelled academically, and became the first college graduate to emerge from the Heilongjiang Children's Welfare Institute. After graduating, she declined many well-paying job offers and chose to dedicate herself to civil affairs and charity work, contributing to the welfare of children and spreading love. Started in July 2006, the hospital has insisted on providing congenital heart disease screenings in remote counties in various provinces across China. Over the years, the screening vehicles have traveled to 18 provinces and regions, including Ningxia, Gansu, Yunnan, Guizhou, to provide congenital heart disease screenings. Their total distance covered has already exceeded 1.3 million kilometers, equivalent to circling the Earth's equator more than 32 times. Supporting underprivileged children with congenital heart disease has become an integral part of Teda International Cardiovascular Hospital's mission. President Liu Xiaocheng emphasized their comprehensive approach, from initial screening and diagnosis to evaluating surgical criteria, admission, surgery, recovery, discharge, and follow-ups. The hospital has developed a sophisticated and well-organized process. Regardless of the complexity of the cases, they make rigorous and through treatment plans. Every aspect related to the children's well-being, no matter how small, is handled with care and attention. The charitable acts of Teda International Cardiovascular Hospital not only exemplify the hospital's humanitarian spirit but also showcase the noble dedication of healthcare professionals to society, providing a perfect embodiment of medical philanthropy and social responsibility. SOURCE China Daily

AHA

100 Deals associated with TEDA International Cardiovascular Hospital

100 Translational Medicine associated with TEDA International Cardiovascular Hospital

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 23 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Mesenchymal Stem Cells( Beijing Yuanhefa Biotechnology)	Acute myocardial infarction More	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis